Companies Precision Biosciences
Precision Biosciences (DTIL): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Precision Biosciences’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $2,039,280FY2023
- $4,310,914FY2024
- $2,189,467FY2025
CEO total pay was $2,189,467 in fiscal 2025, down from $4,310,914 in fiscal 2024.
FY2025: salary $650,875 · bonus $451,294 · stock awards $1,025,086 · option awards $0
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Michael Amoroso | $650,875 | $451,294 | $1,025,086 | $0 | $0 | $0 | $62,212 | $2,189,467 |
| President, Chief Executive Officer and Director | ||||||||
| Alex Kelly | 472,525 | 222,220 | 417,060 | 0 | 0 | 0 | 22,311 | 1,134,116 |
| Chief Financial Officer | ||||||||
| Dario Scimeca | 445,875 | 193,558 | 252,000 | 0 | 0 | 0 | 20,208 | 911,641 |
| General Counsel and Secretary | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Michael Amoroso | $2,189,467 | $4,310,914 | $2,039,280 | ↓ −2,121,447 |
| Alex Kelly | 1,134,116 | 1,893,387 | 1,084,388 | ↓ −759,271 |
| Dario Scimeca | 911,641 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
We believe that equity awards provide our executives with a strong link to our long-term performance, create an ownership culture and help to align the interests of our executives and our stockholders.
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Alex Kelly | RSU | — | — | — | — | — | $417,060 |
| Michael Amoroso | RSU | — | — | — | — | — | 1,025,086 |
| Dario Scimeca | RSU | — | — | — | — | — | 252,000 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Alex Kelly | $417,060 | $0 | $0 | 0.0% |
| Michael Amoroso | 1,025,086 | 0 | 0 | 0.0% |
| Dario Scimeca | 252,000 | 0 | 0 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Dario Scimeca | RSU | 1,978 | — | $8,228 |
| Michael Amoroso | Option | 2,083 | 41.4 | — |
| Alex Kelly | RSU | 3,888 | — | 16,174 |
| Michael Amoroso | RSU | 8,888 | — | 36,974 |
| Dario Scimeca | RSU | 16,850 | — | 70,096 |
| Alex Kelly | RSU | 27,801 | — | 115,652 |
| Dario Scimeca | RSU | 29,815 | — | 124,030 |
| Dario Scimeca | RSU | 50,000 | — | 208,000 |
| Alex Kelly | RSU | 53,150 | — | 221,104 |
| Michael Amoroso | RSU | 74,138 | — | 308,414 |
| Alex Kelly | RSU | 82,750 | — | 344,240 |
| Michael Amoroso | RSU | 138,842 | — | 577,583 |
| Michael Amoroso | RSU | 203,390 | — | 846,102 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Stanley R. Frankel, M.DNot independent · Science and Technology (Chair) | $52,250 | $108,150 | $0 | $0 | $173,800 | $334,200 |
| Kevin J. BuehlerIndependent · Board Chair · Lead Independent Director · Audit · Nominating/Governance | 84,500 | 108,150 | 0 | 0 | 0 | 192,650 |
| Geno GermanoIndependent · Audit · Compensation (Chair) · Science and Technology | 65,750 | 108,150 | 0 | 0 | 0 | 173,900 |
| Melinda BrownIndependent · Audit (Chair) · Compensation | 55,000 | 108,150 | 0 | 0 | 0 | 163,150 |
| Shari Lisa PiréIndependent · Compensation · Nominating/Governance (Chair) | 54,250 | 108,150 | 0 | 0 | 0 | 162,400 |
| Michael AmorosoEmployee director | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 7,500 / 6,250 / 3,750 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $311,750 |
| Equity awards (grant-date value) | $540,750 |
| All other compensation | $173,800 |
| Total cost of the board | $1,026,300 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Precision Biosciences as a peer
Companies that benchmark against DTIL
7 companies name DTIL as a compensation peer
- Adaptimmune Therapeutics PLCADAPFY2024
- AGENUS INCAGENFY2025
- ASSEMBLY BIOSCIENCES, INC.ASMBFY2025
- Generation Bio Co.GBIOFY2024
- KYNTRA BIO, INC.FGENFY2025
- Passage BIO, Inc.PASGFY2025
- Shattuck Labs, Inc.STTKFY2025
Each company listed discloses DTIL in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named DTIL in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Precision Biosciences | 2025 | Michael Amoroso | $650,875 | $1,025,086 | $0 | $0 | $2,189,467 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-21 | 18,696,193 | 612,836 | 18,504 | 96.83% | Passed |
| 2025 | 2025-05-28 | 3,389,745 | 261,406 | 102,189 | 92.84% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-05-21 | 96.83%a |
| 2025 | 2025-05-28 | 92.84%b |
a. Approved under the standard stated in the filing — “(3) Abstentions are not counted as "votes cast" and thus will have no effect on the approval of this proposal.”.
b. Approved under the standard stated in the filing — “(3) Abstentions are not counted as "votes cast" and thus will have no effect on the approval of this proposal.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Geno Germano | Director | 2026-05-20 | A | 21,000 | — | — | Common | Form 4 ↗ |
| Shari Lisa Pire | Director | 2026-05-20 | D | 21,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Melinda Brown | Director | 2026-05-20 | D | 21,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Melinda Brown | Director | 2026-05-20 | A | 21,000 | — | — | Common | Form 4 ↗ |
| Stanley Frankel | Director | 2026-05-20 | D | 21,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stanley Frankel | Director | 2026-05-20 | A | 21,000 | — | — | Common | Form 4 ↗ |
| Kevin J. Buehler | Director | 2026-05-20 | D | 21,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin J. Buehler | Director | 2026-05-20 | A | 21,000 | — | — | Common | Form 4 ↗ |
| Shari Lisa Pire | Director | 2026-05-20 | A | 21,000 | — | — | Common | Form 4 ↗ |
| Geno Germano | Director | 2026-05-20 | D | 21,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Alex Kelly | Chief Financial Officer | 2026-06-01 | A | 193,688 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dario Scimeca | General Counsel and Secretary | 2026-06-01 | A | 107,604 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| J. Jefferson Smith | Chief Research Officer | 2026-06-01 | A | 57,389 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Amoroso | Director | 2026-06-01 | A | 573,888 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin J. Buehler | Director | 2026-06-03 | A | 20,979 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shari Lisa Pire | Director | 2026-06-03 | A | 20,979 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stanley Frankel | Director | 2026-06-03 | A | 20,979 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Geno Germano | Director | 2026-06-03 | A | 20,979 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Melinda Brown | Director | 2026-06-03 | A | 20,979 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Geno Germano | Director | 2026-09-25 | A | 2,609 | 6 | 16,385 | Common | Form 4 ↗ |
| Melinda Brown | Director | 2026-09-25 | A | 1,135 | 6 | 7,116 | Common | Form 4 ↗ |
| Stanley Frankel | Director | 2026-09-28 | A | 1,000 | 6 | 6,000 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (41 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Michael Amoroso. DEF 14A, filed 2026-04-08. Section “Summary Compensation Table” · page 39. As printed: 2,189,467. View filing ↗
- Section 01, Alex Kelly. DEF 14A, filed 2026-04-08. Section “Summary Compensation Table” · page 39. As printed: 1,134,116. View filing ↗
- Section 01, Dario Scimeca. DEF 14A, filed 2026-04-08. Section “Summary Compensation Table” · page 39. As printed: 911,641. View filing ↗
- Section 03, Alex Kelly RSU. DEF 14A, filed 2026-04-08. Section “FUNCTION-DMD” · grants of plan-based awards table. View filing ↗
- Section 03, Michael Amoroso RSU. DEF 14A, filed 2026-04-08. Section “FUNCTION-DMD” · grants of plan-based awards table. View filing ↗
- Section 03, Dario Scimeca RSU. DEF 14A, filed 2026-04-08. Section “FUNCTION-DMD” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. 10-K, filed 2026-03-12. Section “CEO Pay Ratio”. As printed: —. View filing ↗
- Section 08, Stanley R. Frankel, M.D. DEF 14A, filed 2026-04-08. Section “Director Compensation”. As printed: 334,200. View filing ↗
- Section 08, Kevin J. Buehler. DEF 14A, filed 2026-04-08. Section “Director Compensation”. As printed: 192,650. View filing ↗
- Section 08, Geno Germano. DEF 14A, filed 2026-04-08. Section “Director Compensation”. As printed: 173,900. View filing ↗
- Section 08, Melinda Brown. DEF 14A, filed 2026-04-08. Section “Director Compensation”. As printed: 163,150. View filing ↗
- Section 08, Shari Lisa Piré. DEF 14A, filed 2026-04-08. Section “Director Compensation”. As printed: 162,400. View filing ↗
- Section 08, Michael Amoroso. DEF 14A, filed 2026-04-08. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Geno Germano 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Shari Lisa Pire 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Melinda Brown 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Melinda Brown 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stanley Frankel 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stanley Frankel 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin J. Buehler 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin J. Buehler 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Shari Lisa Pire 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Geno Germano 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alex Kelly 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dario Scimeca 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, J. Jefferson Smith 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Amoroso 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin J. Buehler 2026-06-03. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Shari Lisa Pire 2026-06-03. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stanley Frankel 2026-06-03. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Geno Germano 2026-06-03. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Melinda Brown 2026-06-03. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Geno Germano 2026-09-25. Form 4, filed 2026-09-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Melinda Brown 2026-09-25. Form 4, filed 2026-09-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stanley Frankel 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-05-26. Item 5.07 · say-on-pay result. As reported: 96.83% (votes for as printed: 18,696,193). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-03. Item 5.07 · say-on-pay result. As reported: 92.84% (votes for as printed: 3,389,745). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 311,750 + equity 540,750 + all other 173,800 = 1,026,300, summed across the director compensation table rows.
- Precision Biosciences (subject), Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in Precision Biosciences's own proxy. As printed: 2,189,467. View filing ↗